Network medicine and health services research in urology

It’s the intention of the Medical Informatics Funding Scheme and different nationwide and native tasks for digital networking in healthcare to facilitate the trade and use of affected person knowledge between establishments in compliance with knowledge safety laws.
This requires the mixing of information from varied sources-such as digital office methods, laboratory methods, image archiving and communication (PAC) methods or tumor boards-into a knowledge warehouse or analysis databases. Digital networking of service suppliers and analysis establishments will open entry to high-performance and precision medication (e.g., digital molecular tumor boards) for much more sufferers, thereby offering knowledge for primary and care analysis.
Community medication will set up the translational hyperlink between primary analysis (e.g., genome analysis) and affected person care. Digitally built-in “actual world” affected person knowledge will even facilitate an in depth evaluation of well being care and the standard of therapies.

Robotics in Pediatric Urology: Evolution and the Future

Virtually 30 years have handed for the reason that inception of minimally invasive surgical procedure in urology and particularly in pediatric urology. Laparoscopy has now grow to be an important software within the pediatric urologic armamentarium. The applying of robot-assisted surgical procedure in pediatrics has allowed for widespread utilization for widespread reconstructive procedures similar to pyeloplasty and ureteral reimplantation.
Understanding the implementation, technical concerns, and outcomes are crucial for continued success and adoption. This has allowed for elevated use in additional complicated urologic procedures similar to redo pyeloplasty, dismembered ureteral reimplantation, catheterizable channel creation, and bladder augmentation.

The Significance of Reporting Scientific and Epidemiological Knowledge in Urology: Native Experiences and Insights from the Worldwide Literature

Pathologies of the genito-urinary tract are chargeable for a substantial illness burden worldwide, resulting in vital losses of earnings, misplaced working days, elevated expenditures for nationwide healthcare methods, and decreased high quality of life (QoL) within the affected sufferers. Amongst these ailments, infections and malignancies on this anatomical area are a few of the most necessary sicknesses in human medication; however, benign prostate hyperplasia (BPH), erectile dysfunction, hypospadias, urinary incontinence, and vesicoureteral reflux are additionally related issues affecting hundreds of thousands.
The publication of assorted microbiological and medical research in urology from totally different geographical areas has necessary ramifications from the standpoint of epidemiology: on one hand, reported knowledge might affect the event of therapeutic tips for urinary tract infections (UTIs) (empiric antibiotic-therapy) and malignancies (together with classical cytotoxic drug protocols and next-generation anticancer therapies) each regionally and internationally; alternatively, the related stakeholders and authorities representatives usually base their choices on printed proof.
Due to this fact, novel research within the subject of urology are strongly inspired to keep up and enhance the excessive commonplace of affected person care internationally and to make sure steady data provide for worldwide datasets on the causative brokers of UTIs and most cancers registries. The current Editorial goals to spotlight some related research printed from the sphere of urology in Medicina during the last a number of years.

Cannabinoids in urology. Which benign circumstances may they be acceptable to deal with: A scientific assessment

There’s rising proof suggesting cannabinoids might present appropriate alternate options to traditional therapies in an growing variety of medical settings. This assessment evaluates how cannabinoids are used to deal with sure benign urological pathologies and to make clear the medical worth of this knowledge.
This assessment consists of 62 papers and was undertaken per PRISMA’s tips, it evidences the therapeutic potential of cannabinoids within the administration of particular benign urological ailments, most notably neurogenic bladder dysfunction (medical research), renal illness (animal research) and interstitial cystitis (animal research). Nevertheless, while cannabinoids are more and more used, they can’t be thought-about dependable alternate options to extra recognised therapies.
Network medicine and health services research in urology

Ckj consolidation amongst Q1 Urology and Nephrology journals

The Scientific Kidney Journal (ckj) affect issue from Clarivate’s Net of Science for 2019 was 3.388. This consolidates ckj amongst journals within the high 25% (first quartile, Q1) within the Urology and Nephrology subject based on the journal affect issue.
The manuscripts contributing probably the most to the affect issue targeted on power kidney illness (CKD) epidemiology and analysis, CKD problems and their administration, cost-efficiency of renal substitute remedy, pathogenesis of CKD, familial kidney illness and the environment-genetics interface, onconephrology, expertise, SGLT2 inhibitors and consequence prediction. We offer right here an summary of the most well liked and most impactful matters for 2017-19.

Black pearl in urology: Inadvertent anastomosis of gonadal vein to ureter resulting in malpostioning of stent into the inferior vena cava

Double- J (JJ) stents are generally utilized in urological procedures. Minor and self limiting problems are widespread following JJ stenting. Malpositioning of JJ stent into the vascular system is a uncommon and a probably deadly complication. We’re reporting a case of a malpositioned JJ stent within the inferior vena cava (IVC), throughout Boari flap process for post-hysterectomy uretereovaginal fistula.
Affected person had undergone hysterectomy three months beforehand, and had ureterovaginal fistula probably attributable to iatrogenic intraoperative damage. Affected person underwent right-sided ureteroneocystostomy with Boari flap one week beforehand at different institute. Affected person was admitted in our establishment with complaints of fever, ache in stomach and vomiting.

anti-Galectin 1

YF-PA12945 100 ug
EUR 403
Description: Rabbit polyclonal to Galectin 1

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 349

Anti-Galectin 1 Antibody

A00470-2 100ug/vial
EUR 294

Anti-Galectin-1 antibody

STJ98716 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-1.

Anti-Galectin-1 antibody

STJ93201 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-1.

anti- Galectin-1 antibody

FNab03314 100µg
EUR 505.25
Description: Antibody raised against Galectin-1

anti- Galectin-1 antibody

FNab03315 100µg
EUR 548.75
Description: Antibody raised against Galectin-1

Anti-Galectin-1 antibody

PAab03314 100 ug
EUR 355

Anti-Galectin 1 (1A8)

YF-MA13984 100 ug
EUR 363
Description: Mouse monoclonal to Galectin 1

Anti-Galectin 1/LGALS1 Antibody

PA1422 100ug/vial
EUR 334

Anti-Galectin 1/LGALS1 Antibody

PB9240 100ug/vial
EUR 334

Anti-Galectin 1/Lgals1 Antibody

A00470 100ug/vial
EUR 334

Anti-Galectin 1 Biotinylated Antibody

A00470-Biotin 50ug/vial
EUR 294

Anti-galectin-1 (mouse) antibody

STJ72519 100 µg
EUR 359

anti-Galectin 1 (1E8-1B2)

LF-MA10174 100 ug
EUR 363
Description: Mouse monoclonal to Galectin 1

Anti-Galectin-13 (GAL13) / Placental Protein 13 (PP13) Monoclonal Antibody

M08143-1 100ug/vial
EUR 397
Description: Mouse Monoclonal Galectin-13 (GAL13) / Placental Protein 13 (PP13) Antibody. Validated in IHC and tested in Human.

anti-Galectin 3

YF-PA12946 50 ug
EUR 363
Description: Mouse polyclonal to Galectin 3

anti-Galectin 3

YF-PA12947 100 ul
EUR 403
Description: Rabbit polyclonal to Galectin 3

anti-Galectin 3

YF-PA12948 100 ug
EUR 403
Description: Rabbit polyclonal to Galectin 3

anti-Galectin 8

YF-PA12951 50 ul
EUR 363
Description: Mouse polyclonal to Galectin 8

anti-Galectin 3

YF-PA24079 50 ul
EUR 334
Description: Mouse polyclonal to Galectin 3

anti-galectin 9

YF-PA24081 50 ul
EUR 334
Description: Mouse polyclonal to galectin 9

anti-Galectin 13

YF-PA18585 50 ug
EUR 363
Description: Mouse polyclonal to Galectin 13

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

Anti-human Galectin-3 antibody

STJ15100163 250 µg
EUR 336
Description: This monoclonal antibody is for studies of antigen expression in cells and tissue sections using immunocytochemistry and immunoprecipitation

LGALS7 Human, Galectin-7 Human Recombinant Protein, His Tag

PROTP47929-1 Regular: 20ug
EUR 317
Description: Galectin-7 Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 156 amino acids (1-136 a.a.) and having a molecular mass of 17.2kDa. ;The Galectin-7 is purified by proprietary chromatographic techniques.

LGALS3 Human, Galectin-3 Human Recombinant Protein, His Tag

PROTP17931-1 Regular: 25ug
EUR 317
Description: LGALS3 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 270 amino acids (1-250 a.a.) and having a molecular mass of 28.3 kDa._x000D_ The LGALS3 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. _x000D_

LGALS8 Human, Galectin-8 Human Recombinant Protein, His Tag

PROTO00214-1 Regular: 10ug
EUR 317
Description: LGALS8 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 337 amino acids (1-317 a.a.) and having a molecular mass of 37.9 kDa. The LGALS8 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques.

Human Galectin-3 (Gal-3) AssayMax ELISA Kit

EG3311-1 96 Well Plate
EUR 477

Human Galectin-4 (Gal-4) AssayMax ELISA Kit

EG3312-1 96 Well Plate
EUR 477

Human Galectin-1 (LGALS1)

1-CSB-EP012882HU
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli

Human Galectin-1 (LGALS1)

1-CSB-EP012882HUb1
  • EUR 380.00
  • EUR 214.00
  • EUR 1309.00
  • EUR 560.00
  • EUR 873.00
  • EUR 262.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Human Galectin-1(LGALS1) expressed in E.coli

Human Galectin 1 Protein

20-abx066725
  • EUR 620.00
  • EUR 272.00
  • EUR 1859.00
  • EUR 732.00
  • EUR 453.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Recombinant Human Galectin-1

7-00427 10µg Ask for price

Recombinant Human Galectin-1

7-00428 50µg Ask for price

Recombinant Human Galectin-1

7-00429 1mg Ask for price

Galectin-1, human recombinant

4648-10
EUR 142

Galectin-1, human recombinant

4648-1000
EUR 1648

Galectin-1, human recombinant

4648-50
EUR 262

Anti-Galectin-3 antibody

STJ16100369 1 mL
EUR 1047

Anti-Galectin-3 antibody

STJ16100782 100 µg
EUR 720

Anti-Galectin-3 antibody

STJ180106 0.1 ml
EUR 212

Anti-Galectin 3 antibody

STJ190057 200 µl
EUR 197
Description: Unconjugated Mouse monoclonal to Galectin 3 (AS1A24)

Anti-Galectin-9 Antibody

A03415 100ul
EUR 397
Description: Rabbit Polyclonal Antibody for Galectin-9 Antibody (LGALS9) detection.tested for WB in Human, Mouse, Rat.

Anti-Galectin-3 antibody

STJ96945 200 µl
EUR 197
Description: Galectin-3 is a protein encoded by the LGALS3 gene which is approximately 26,1 kDa. Galectin-3 is localised to the cytoplasm and nucleus. It is involved in NF-kappaB signalling, advanced glycosylation end product receptor signalling and cell adhesion. It is a galactose-specific lectin which binds IgE and may mediate the stimulation by CSPG4 of endothelial cells migration along with the alpha-3, beta-1 integrin. It is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. Galectin-3 is expressed mainly in the colonic epithelium and is also abundantly expressed in activated macrophages. Mutations in the LGALS3 gene may result in follicular adenoma and thyroid cancer. STJ96945 was developed from clone 6G2 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous galectin-3 proteins.

Anti-Galectin-3 antibody

STJ97549 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (6B8).

Anti-Galectin-3 antibody

STJ97550 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (8D7).

Anti-Galectin-3 antibody

STJ97551 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (5D9).

Anti-Galectin-3 antibody

STJ97601 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (2F9).

Anti-Galectin-3 antibody

STJ97604 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (16E6).

Anti-Galectin-3 antibody

STJ97605 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3 (1H4).

Anti-Galectin-3 antibody

STJ97715 200 µl
EUR 197
Description: Mouse monoclonal to Galectin-3.

Anti-Galectin-2 antibody

STJ93202 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-2.

Anti-Galectin-4 antibody

STJ93203 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-4.

Anti-Galectin-7 antibody

STJ93204 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-7.

Anti-Galectin-8 antibody

STJ93205 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-8.

Anti-Galectin-9 antibody

STJ93206 200 µl
EUR 197
Description: Rabbit polyclonal to Galectin-9.

Anti-Galectin 3 antibody

STJ73098 100 µg
EUR 359

anti- Galectin 2 antibody

FNab03310 100µg
EUR 585
Description: Antibody raised against Galectin 2

anti- Galectin 4 antibody

FNab03311 100µg
EUR 505.25
Description: Antibody raised against Galectin 4

anti- Galectin 8 antibody

FNab03312 100µg
EUR 505.25
Description: Antibody raised against Galectin 8

anti- Galectin 9 antibody

FNab03313 100µg
EUR 505.25
Description: Antibody raised against Galectin 9

anti- Galectin-3 antibody

FNab03316 100µg
EUR 505.25
Description: Antibody raised against Galectin-3

anti- Galectin-3 antibody

FNab03317 100µg
EUR 548.75
Description: Antibody raised against Galectin-3

anti- Galectin-7 antibody

FNab03318 100µg
EUR 505.25
Description: Antibody raised against Galectin-7

anti-Galectin-3 (6G2)

LF-MA20336 100 ug
EUR 354
Description: Mouse monoclonal to Galectin-3

Anti-Galectin 2 antibody

PAab03310 100 ug
EUR 412

Anti-Galectin 4 antibody

PAab03311 100 ug
EUR 355

Anti-Galectin 8 antibody

PAab03312 100 ug
EUR 355

Anti-Galectin 9 antibody

PAab03313 100 ug
EUR 355

Anti-Galectin-3 antibody

PAab03316 100 ug
EUR 355

Anti-Galectin-7 antibody

PAab03318 100 ug
EUR 355

Anti-Galectin 8 (3E5)

YF-MA13986 100 ug
EUR 363
Description: Mouse monoclonal to Galectin 8

Anti-galectin-1 (mouse) (aa100-112) antibody

STJ72520 100 µg
EUR 359

Anti Human Galectin-3 Polyclonal Antibody

KH040
EUR 649
Description: The Anti Human Galectin-3 Polyclonal Antibody is available in Europe and for worldwide shipping via Gentaur.

Anti-Galectin-1 / Human Placental Lactogen (hPL) Monoclonal Antibody

M00470 100ug/vial
EUR 397
Description: Mouse Monoclonal Galectin-1 / Human Placental Lactogen (hPL) Antibody. Validated in IHC and tested in Human.

Galectin-1 (LGAS1)

PR27143 50 ug
EUR 318

Galectin 1 Antibody

49673-100ul 100ul
EUR 333

Galectin 1 Antibody

49673-50ul 50ul
EUR 239

Galectin-1 Protein

20-abx261634
  • EUR 3418.00
  • EUR 328.00
  • EUR 230.00
  • 1 mg
  • 20 ug
  • 5 ug

Galectin-1 Protein

20-abx263505
  • EUR 230.00
  • EUR 1790.00
  • EUR 328.00
  • 10 ug
  • 1 mg
  • 50 ug

rHu Galectin-1

AK8281-0010 10µg Ask for price

rHu Galectin-1

AK8281-0050 50µg Ask for price

rHu Galectin-1

AK8281-0100 100µg Ask for price

rHu Galectin-1

AK8281-1000 1mg Ask for price

Galectin-1 Antibody

3596-100
EUR 316

Galectin-1 Antibody

3596-30T
EUR 146

Galectin 1 protein

30R-1385 100 ug
EUR 224
Description: Purified recombinant Human Galectin 1 protein

Galectin 1 protein

30R-2371 50 ug
EUR 353
Description: Purified recombinant Human Galectin 1 protein

Galectin 1 protein

30R-AG003 10 ug
EUR 133
Description: Purified recombinant Human Galectin 1 protein

Galectin 1 antibody

70R-11939 100 ug
EUR 403
Description: Rabbit polyclonal Galectin 1 antibody

Galectin 1 antibody

70R-13963 100 ug
EUR 322
Description: Affinity purified Rabbit polyclonal Galectin 1 antibody

Galectin 1 antibody

70R-49997 100 ul
EUR 244
Description: Purified Polyclonal Galectin 1 antibody
In view of the signs of the affected person, cross-sectional imaging with computed tomography scan was completed which revealed an intraoperatively malpositioned JJ stent within the IVC, and nicely healed Boari flap was seen.